More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.20B
EPS
-0.02
P/E ratio
--
Price to sales
6.86
Dividend yield
--
Beta
0.966553
Previous close
$3.38
Today's open
$3.36
Day's range
$3.25 - $3.37
52 week range
$2.28 - $3.91
CEO
Michael Gorenstein
Employees
356
Headquarters
Stayner, ON
Exchange
NASDAQ Global Market
Shares outstanding
366471299
Issue type
Common Stock
Healthcare
Pharmaceuticals
One Regulator Could Soon Unlock Altria And Cronos' Cannabis Fortune
Altria remains fundamentally well-positioned for U.S. cannabis entry, primarily through its 42% stake in Cronos Group. MO's core tobacco business continues to generate robust cash flow, with Q2 2026 adjusted EPS up 2.8% and a 4.7% dividend increase. Cronos delivered record Q3 results, maintains a strong balance sheet, and is expanding internationally, setting up for potential U.S. market entry.
Seeking Alpha • Nov 9, 2026

Cronos Group Inc. (CRON:CA) Q3 2026 Earnings Call Transcript
Cronos Group Inc. (CRON:CA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 7, 2026

Cronos Group Q3 Earnings Call Highlights
Cronos Group NASDAQ: CRON reported record third-quarter revenue, gross profit and adjusted EBITDA as cannabis sales grew in Israel, Canada and Germany, while executives outlined plans to expand in Europe following the company's acquisition of Dutch cannabis producer CanAdelaar.
MarketBeat • Nov 5, 2026

Cronos Group Reports 2026 Third Quarter Results
Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count
GlobeNewsWire • Nov 5, 2026

Cronos Group (CRON) Q3 Earnings and Revenues Beat Estimates
Cronos Group (CRON) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.07 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Here is how Cronos Group (CRON) and Amgen (AMGN) have performed compared to their sector so far this year.
Zacks Investment Research • Oct 26, 2026

Cronos (CRON) Upgraded to Strong Buy: Here's What You Should Know
Cronos (CRON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks Investment Research • Oct 23, 2026

Cronos Completes Acquisition of CanAdelaar, Europe's Largest Adult-Use Cannabis Company
Cronos acquires CanAdelaar for a base purchase price of €57.5 million plus cash earnout of 0.5x Normalized EBITDA 1 in 2026 and 2027
GlobeNewsWire • Oct 15, 2026

Fan-Favorite and Limited-Edition Spinach® Green Apple-Flavored Products are Returning for the Fall Season
TORONTO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, announced today that for the third consecutive year it is bringing back its popular limited-edition Caramel Green Apple flavor to its best-selling lineup of SOURZ by Spinach® edibles. For the first time, this seasonal flavor will launch exclusively in the SOURZ by Spinach® Fully Blasted 10-pack, the #1 edible multipack in Canada1.
GlobeNewsWire • Oct 13, 2026

CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
Cronos Group stock climbs 17% in three months on strong revenue growth and margin gains, but rising competition and regulatory risks raise questions about its upside.
Zacks Investment Research • Oct 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cronos Group Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.